Drugs that contain Linaclotide

1. List of Linzess drug patents

Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7371727 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(11 months from now)

US7704947 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(11 months from now)

US8080526 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(11 months from now)

US7745409 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(11 months from now)

US7304036 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Aug, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8110553 ALLERGAN Methods and compositions for the treatment of gastrointestinal disorders
Jan, 2024

(11 months from now)

US8933030 ALLERGAN Treatments for gastrointestinal disorders
Feb, 2031

(8 years from now)

US10702576 ALLERGAN Stable formulations of linaclotide
Aug, 2031

(8 years from now)

US10675325 ALLERGAN Stable formulations of linaclotide
Aug, 2031

(8 years from now)

US8748573 ALLERGAN Formulations comprising linaclotide
Oct, 2031

(8 years from now)

US8802628 ALLERGAN Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration
Oct, 2031

(8 years from now)

US9708371 ALLERGAN Treatments for gastrointestinal disorders
Aug, 2033

(10 years from now)

Market Authorisation Date: 30 August, 2012

Treatment: Method of treating irritable bowel syndrome with constipation in adults; Method of treating chronic idiopathic constipation in adult patients.; Method of treating irritable bowel syndrome with constipation in adult patients.

Dosage: CAPSULE;ORAL

How can I launch a generic of LINZESS before it's patent expiration?
More Information on Dosage

LINZESS family patents

83

United States

22

Japan

12

Korea, Republic of

11

European Union

10

Mexico

10

China

8

Spain

8

Canada

7

Australia

7

Denmark

5

Slovenia

5

Portugal

4

Brazil

4

Poland

4

Hungary

4

South Africa

4

Russia

4

Singapore

4

New Zealand

3

Hong Kong

3

Lithuania

3

Cyprus

3

Norway

2

Austria

2

RS

2

Luxembourg

2

Ukraine

2

Germany

2

Israel

2

Argentina

2

Peru

2

EA

2

Croatia

1

Chile

1

Uruguay

1

Netherlands

1

Colombia

1

Georgia

1

Turkey

1

Philippines

1

Taiwan, Province of China

1

Ecuador

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic